Breaking News Bar
updated: 1/23/2013 9:56 AM

Abbott profit falls on separation costs

hello
Success - Article sent! close
  • Abbott Labs headquarters

       Abbott Labs headquarters
    STEVE LUNDY | Staff Photographer

 
Associated Press

Libertyville Township-based Abbott Laboratories said Wednesday its profit fell 35 percent in the fourth quarter on costs from the spin-off of its drug business into the new company Abbvie.

On Jan. 1 Abbott completed the split, leaving it with a business model built around generic drugs, medical implants and nutritional formula. Abbvie will market the company's branded prescription drugs, including the blockbuster anti-inflammatory drug Humira.

In Abbott's last quarter as a combined unit, the company earned $1.05 billion, or 66 cents per share, down from $1.62 billion, or $1.02 in the last quarter of 2011.

Earnings were weighed down by a number of one-time charges, including $265 million in separation costs. Excluding that and other charges Abbott would have earned $1.51 per share. The company's revenue increased 4 percent to $10.84 billion, from $10.38 billion in the 2011 fourth quarter.

Analysts polled by FactSet, on average, expected earnings per share of 70 cents per share, on revenue of $10.61 billion.

The higher revenue was led by sales of Humira, which increased 23 percent to $2.68 billion. Sales of nutritionals increased 10 percent to $1.7 billion.

For the coming year, Abbott expects earnings per share between $1.98 and $2.04. Wall Street, on average, was forecasting $1.96 per share, with estimates ranging from $1.56 to $2.10.

Abbvie is scheduled to report its earnings on Jan. 30.

In morning trading Abbott Laboratories' shares slipped 12 cents to $32.78.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.